Sculptor Capital’s ImmunityBio IBRX Stock Holding History

Sculptor Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$684K	Sell	89,200 -530,800	-86%	-$3.63M	0.01%	260
2025 Q4	$1.23M	Hold	620,000	–	–	0.01%	266
2025 Q3	$1.53M	Hold	620,000	–	–	0.02%	238
2025 Q2	$1.64M	Buy	620,000 +567,000	+1,070%	+$1.52M	0.02%	227
2025 Q1	$160K	Sell	53,000 -218,800	-81%	-$663K	﹤0.01%	264
2024 Q4	$696K	Buy	271,800 +53,000	+24%	+$221K	0.01%	227
2024 Q3	$814K	Hold	218,800	–	–	0.01%	204
2024 Q2	$1.38M	Sell	218,800 -47,400	-18%	-$313K	0.03%	155
2024 Q1	$1.43M	Buy	+266,200	New	+$1.21M	0.03%	149
2023 Q4	–	Sell	-131,300	Closed	-$222K	–	386
2023 Q3	$222K	Hold	131,300	–	–	﹤0.01%	234
2023 Q2	$365K	Buy	131,300 +82,100	+167%	+$232K	0.01%	223
2023 Q1	$89.5K	Hold	49,200	–	–	﹤0.01%	320
2022 Q4	$249K	Hold	49,200	–	–	﹤0.01%	479
2022 Q3	$245K	Buy	+49,200	New	+$224K	﹤0.01%	654
2022 Q1	–	Sell	-153,300	Closed	-$932K	–	1265
2021 Q4	$932K	Hold	153,300	–	–	0.01%	689
2021 Q3	$1.49M	Hold	153,300	–	–	0.01%	527
2021 Q2	$2.19M	Sell	153,300 -4,800	-3%	-$79.3K	0.02%	495
2021 Q1	$3.75M	Buy	158,100 +151,300	+2,225%	+$3.92M	0.03%	328
2020 Q4	$91K	Buy	+6,800	New	+$65.4K	﹤0.01%	470

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sculptor Capital's IBRX Position: Q1 2026 in Review

Sculptor Capital reduced its ImmunityBio (IBRX) stake by 86% in Q1 2026, selling an estimated $3.63M and leaving 89,200 shares worth $684K. The position accounts for 0.01% of the portfolio, ranked #259.

Sculptor Capital first reported a position in IBRX in Q4 2020 and has held it in 19 quarters since. The position peaked at $3.75M in Q1 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Sculptor Capital held 89,200 shares of ImmunityBio worth $684K as of Q1 2026.
Sculptor Capital sold 529,800 ImmunityBio shares in Q1 2026, an estimated $3.63M.
ImmunityBio made up 0.01% of Sculptor Capital's portfolio in Q1 2026, its #259 holding.
Sculptor Capital first reported a position in ImmunityBio in Q4 2020 and has held it in 19 quarters since.
Sculptor Capital's ImmunityBio position peaked at $3.75M in Q1 2021.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.